In a computer modeling study, treating a patient in METAVIR stage F3 disease instead of stage F2 increased the risk of liver-related death from 5% to 10%, according to Cindy Zahnd, a research assistant at the University of Bern in Switzerland.
And if successful HCV treatment was delayed until stage F4, the risk of liver-related death rose to 25%, compared with therapy at stage F2, Zahnd said here at the 2015 Conference on Retroviruses and Opportunistic Infections.
That’s because “people who are living with HIV have many other risk factors that maintain them at a certain risk even after HCV clearance,” Zahnd said.”
Read more at: http://www.medpagetoday.com/MeetingCoverage/CROI/50246
Source: MedPageToday.com – March 1, 1015